Physician profile
Danielle Ronco
NPI 1326462714
$6,392.40
in general payments reported to CMS, 2019-2025
20 companies · $15.32 in 2025
The $15.32 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $886 · 2022: $1,762 · 2023: $1,993 · 2024: $1,736 · 2025: $15.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,698 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,697.53 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,053.98 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $915.09 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $719.06 | 2021-2024 | Rexulti |
| Lundbeck LLC | $691.72 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $541.83 | 2021-2024 | Trintellix |
| Supernus Pharmaceuticals, INC. | $419.52 | 2021-2024 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $399.21 | 2021-2024 | Fanapt, Hetlioz |
| Alkermes, INC. | $379.40 | 2022-2023 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $359.65 | 2021-2022 | |
| Corium, LLC | $202.42 | 2023-2024 | Azstarys, Azstarys |
| Tris Pharma INC | $147.14 | 2022-2024 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $146.55 | 2023-2024 | Auvelity, Sunosi |
| Almatica Pharma LLC | $92.58 | 2022 | |
| Neurocrine Biosciences, INC. | $83.73 | 2022-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $69.68 | 2023-2024 | Quviviq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $40.39 | 2022 | |
| Ironshore Pharmaceuticals INC. | $36.48 | 2021-2023 | Jornay Pm |
| Eisai INC. | $35.93 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.00 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $28.04 | 2024 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ronco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.